Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
|Articles|June 15, 2016
- BioPharm International-06-15-2016
- Volume 2016 ebook
- Issue 1
Preventing Phase III Failures
Author(s)Agnes Shanley
Adopting best practices and collaborating more closely with contract research organizations can help drugs get past Phase III.
Advertisement
Only half of new drugs make it past Phase III. Adopting best practices and collaborating more closely with contract research organizations can help ensure success.
Download the
.
Articles in this issue
over 10 years ago
Contract Service Providers Gear Up to Develop Emerging Therapiesover 10 years ago
Biopharma Service Providers Address a Full Plate of Challengesover 10 years ago
Dealing with Pharmaceutical Supply-Chain Complexitiesover 10 years ago
Keeping it Simple: Collaborating for Success in Drug Deliveryover 10 years ago
Biomanufacturers Demand Higher Quality Standards in 2016over 10 years ago
Outsourcing Industry Marked by Considerable Investments in 2016Advertisement
Related to this article
ADC trials are moving from binary antigen testing to quantitative, multiparameter biomarker models that better predict efficacy and toxicity.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
5